in 11 SSA negative patients it was 246 (127). Similarly, for subjects with antibodies to SSB, von Willebrand factor antigen levels were 196 (113), compared with 231 (105) in subjects without antibodies (all data not significant). There was a correlation between the antinuclear antibody titre and seropositivity to SSA (p<0 01), but not seropositivity to SSB.
Discussion
Vasculitis is a recognised feature of Siogren's syndrome and has been reported to be associated with antibodies to the SSA (Ro) autoantigen.34
This study confirms a previous report of high levels of von Willebrand factor antigen in patients with Sjogren's syndrome.6 Considerably fewer of our patients were positive for SSA or SSB than the >80% of patients reported elsewhere.' 2 We found a strong correlation between a high antinuclear antibody titre and seropositivity for SSA, but were unable to correlate levels of von Willebrand factor antigen with levels of autoantibodies. As von Willebrand factor antigen is becoming recognised as a useful index of assessing vasculitis,5 6 9 10 our data do not support the view that autoantibodies to SSA or SSB, or both, are related directly to vasculitis in Sjogren's syndrome.
